Details of the Drug Combination

General Information of Drug Combination (ID: DCE5LM8)

• Drug Combination Name: Brincidofovir +
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 4.67
  Bliss Independence Score: 4.67
  Loewe Additivity Score: 5.28
  LHighest Single Agent (HSA) Score: 5.33

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.